CanSino's COVID-19 vaccine candidate gets first patent; Phase III trials begin in Russia

Chinese pharmaceutical firm, CanSi Biologics, has reportedly started a late-st trial of a COVID-19 vaccine candidate in Russia. According to international media reports, 5-nCoV, which has alrey been approved for use by China’s military, is furr also set to begin late-st trials in Mexico and Saudi Arabia. Moreover, potential coronavirus vaccine candidate has reportedly won a patent approval from Beijing. 

It was last month that company h anunced that it was in talks with several countries - Saudi Arabia, Russia, Brazil and Chile - to launch Phase III trials. Apart from CanSi Biologics, or Chinese firms, including Sivac Biotech Ltd and China National Pharmaceutical Group Co Ltd (Sipharm), are testing candidates overseas as China has become less conducive for Phase III trials due to its small number of new coronavirus cases. last-st trials is generally required for regulatory approval to distribute a vaccine for public use.

RE:  Russia's COVID-19 Vaccine May Cause Refusal Of Or Vaccines If t Safe: bel Laureate

As per reports, Russia’s state register for clinical trials showed a Phase III study expected to recruit 625 volunteers across eight medical institutes to test safety and effectiveness of 5-nCoV. vaccine reportedly uses evirus to carry antigen from coronavirus into human cells, an approach similar to that of 5-nCoV.

RE: CureVac Doesn't Rule Out Speedy Approval Process For Its Prospective COVID-19 Vaccine

Initial phases showed potential 

Earlier, Qiu Dongxu, executive director and co-founder of CanSi, h said that firm plans to recruit 40,000 participants, across countries, for Phase III trial. vaccine candidate, 5-nCoV, has been jointly developed by CanSi and Beijing Institute of Biotechlogy in Acemy of Military Medical Sciences. According to media reports, both initial phases of clinical testing of candidate vaccine has displayed its potential of preventing COVID-19.

5-nCov was first COVID-19 vaccine candidate in China to go ahe with human testing in March but has been lagging in trial progress since two or experimental vaccines developed by Sivac Biotech and a unit of Sipharm h alrey been approved for Phase III trials.

(Im: Rep/Unsplash) 

RE: UK Urges Elderly, Black And Asian Mirity Groups To Sign Up For COVID-19 Vaccine Trial

RE: Russia To Conduct Clinical Trials Of Its Controversial Coronavirus Vaccine In Saudi Arabia